Biologic approved for atopic dermatitis
The Food and Drug Administration approved dupilumab for children aged 6-11 years with moderate to severe atopic dermatitis. This is the first biologic approved for atopic dermatitis in this age group. The new indication is for children whose disease is not adequately controlled with topical prescription therapies. READ MORE.
For more on COVID-19, visit our Resource Center. All of our latest news is available on MDedge.com.